Earnings season continues to chug along, with a wide variety of companies already delivering their quarterly results. The period has been favorable so far, with S&P 500 earnings expected to be positive again.And this week, two large-cap pharmaceutical companies, Novo Nordisk (NVO) and Eli Lilly (LLY) , are on the reporting docket. As shown in the YTD chart below, the stocks have loosely tracked each other, though LLY’s decline is more pronounced.Image Source: Zacks Investment ResearchLet’s take a closer loo ...

Eli Lilly’s (LLY) top-line growth in the second quarter is expected to have been driven by strong demand for its FDA-approved tirzepatide medicines, diabetes drug Mounjaro and weight loss medicine, Zepbound. Tirzepatide is a dual GIP and GLP-1 receptor agonist. The GLP-1 segment is an important class of drugs for multiple cardiometabolic diseases and is gaining significant popularity. GLP-1 drugs work by mimicking the hormone GLP-1, resulting in weight loss, lowering hemoglobin A1c and reducing cardiovascul ...

Eli Lilly and Company, Pharmaceutical company headquarters in Alcobendas, Madrid, Spain. (Photo by ... [+] Cristina Arias/Cover/Getty Images)Cristina AriasEli Lilly stock (NYSE: LLY) will report its Q2 results on Thursday, August 8. The pharmaceutical giant is expected to garner $10 billion in sales and $2.70 in adjusted earnings per share, per the consensus estimates. All eyes will be on Eli Lilly’s diabetes drug – Mounjaro – and its weight-loss drug – Zepbound. In this note, we discuss some of the trends ...

Eli Lilly is one of the most innovative pharmaceutical companies right now.So far in 2024, the healthcare sector has returned 8.5%. This is roughly on par with the long-term average return of the S&P 500. While that's not too shabby, growth investors may be looking for something a little more enticing.Within the broader healthcare sector, the drug manufacturers market has generated a return of 14.3% so far in 2024 and 17.3% over the last year. One of the biggest players among drug manufacturers is Eli Lilly ...

There's reason to be optimistic about what's to come.You might expect Eli Lilly (LLY -3.36%) to perform as big pharma companies often do: offering progressive earnings gains that translate into a steady increase for the stock over the long term. But in recent times, Lilly hasn't exactly behaved like a slow and steady healthcare player, and instead has taken the path of a fast-moving growth stock.Lilly has jumped about 230% over three years and more than 75% over the past year. The driver of these gains is e ...

wellesenterprises/iStock Editorial via Getty Images Investment thesis My initial bearish thesis about Eli Lilly (NYSE:LLY) did not age well, as the stock slightly outperformed the broader U.S. market since February. It appears that I was too pessimistic in my initial coverage. My valuation analysis suggests that the stock is still massively overvalued, but it looks like investors are ready to ignore the generous premium as long as the company continues delivering massive revenue growth and EPS expansion ...

Recent results from a clinical trial show that treatment with Zepbound significantly reduced patients' risk of heart failure outcomes, including cardiovascular death.Shares of Eli Lilly (LLY -3.36%) notched a 3.5% gain on Thursday, Aug. 1, after the company reported positive clinical trial results for its increasingly successful weight management treatment. It looks like certain patients treated with tirzepatide were significantly less likely to suffer cardiovascular death and other heart failure outcomes c ...

These healthcare stocks are up more than 400% in the past five years, thanks to their dominance in the anti-obesity market.Eli Lilly (LLY -3.36%) and Novo Nordisk (NVO -3.75%) are the two big names dominating the anti-obesity market today. They've been generating billions in revenue from their treatments, and there's still a lot of growth for these companies.However, the weight loss drug that proves to be more effective could ultimately determine which company will capture the lion's share of the market. Th ...

An injection pen of Zepbound, Eli Lilly’s weight loss drug, is displayed in New York City, Dec. 11, 2023.All doses of Eli Lilly's highly popular weight loss injection Zepbound and diabetes drug Mounjaro are now available in the U.S., according to an update on the Food and Drug Administration's drug shortage database on Friday. A previous update said some doses of the treatments were still in short supply. Some doses of Mounjaro have been in shortage since as early as 2022, while doses of Zepbound joined the ...

What's good for Zepbound is good for the company, it seems.It's always a relief when a drug shortage ends. It's even more of a relief when that shortage concerns a hot new drug produced by a high-profile pharmaceutical company.That dynamic was behind the 3.5% increase of Eli Lilly's (LLY 3.50%) stock price on Thursday. Comforting words from the company's leader led investors to load up on the stock, making it a far better performer than the sliding S&P 500 index (which fell by 1.4% that day).Bound for the m ...